Optimal Industrial Technologies will be a co-host sponsor and presenter at Proventa International’s online Biomanufacturing & Cell and Gene Therapy Strategy Meeting. During the roundtable event, Optimal will discuss how Quality by Design (QbD) and Process Analytical Technology (PAT) can help businesses get higher volumes of products to the market faster whilst maintaining or improving product quality. This attests to Optimal’s continuous support for the sector, which is working hard to quickly bring both new and existing therapies to patients in need.

Proventa International’s strategy meetings offer a key opportunity for leaders in pharma, biotech and life science to discuss the biggest challenges in these industries and how to bring drug development strategies to the next level. The upcoming online event on 3rd June will focus on how the biomanufacturing as well as cell and gene therapy sectors can optimise their operations.

As a world leader in PAT data management, Optimal will contribute to the discussion by showcasing how different businesses have benefitted from this quality-driven approach to manufacturing. The company is hosting a round table event, entitled “Current perspectives on the use of QbD and PAT in pharmaceuticals and (bio)pharmaceutical development and manufacturing”, this being led by Martin Gadsby, Director at Optimal Industrial Technologies from 15:30 GMT.

He will discuss real-world examples and key metrics on process improvements such as quality improvements, reductions in cycle and scale-up times, energy saving and production increases. In addition, he will present the crucial role of PAT knowledge management platforms in achieving these results. Currently, the most widely adopted solution is Optimal’s synTQ, which is used by over 60% major pharmaceutical manufacturers.

Martin Gadsby comments: “We are excited to take part in Proventa International’s first online strategy meeting on biomanufacturing & cell and gene therapy. Even in the current global situation, we are working to support pharmaceutical and biomanufacturing businesses, which are under particular pressure as the demand for their products is skyrocketing.

“synTQ can help to increase productivity by three times or more without expanding an operation’s current manufacturing footprint. In addition to this, it can streamline the development of new treatments and medical solutions.”

Attend Optimal’s round table event at Biomanufacturing and Cell & Gene Therapy Online Strategy Meeting on 3rd June 2020 at 15:30 GMT by registering at: https://proventainternational.com/events/manufacturing/online/online-biomanufacturing-and-cell-and-gene-therapy/